🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 75% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size
Other Combinations Product Type
75% Evidence Coverage

Supplement Facts — Evidence Check

Calcium
64 mg (6% DV)
1820 mcg (2275% DV)
📊 15.2× RDA — above typical dose 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 1.82mg
200 mcg (250% DV)
✅ 1.7× RDA — within safe limits 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.2mg
180 mcg (225% DV)
✅ 1.5× RDA — within safe limits 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.18mg

Other Ingredients

Microcrystalline Cellulose Dibasic Calcium Phosphate Hydroxypropylcellulose Magnesium Stearate Silica

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: 1 tablet daily with a meal.

⚠️ Warnings & Precautions

Warning: If you are pregnant, may become pregnant, breastfeeding, or if you are taking anticoagulant drugs such as warfarin (Coumadin), consult your heath care professional before using this product.

Do not use if either tamper-evident seal is broken or missing.

Keep out of the reach of children.

🧪 Formulation Notes

Non GMO

Vitamin K2 Advantage uniquely delivers three powerful forms of vitamin K important to bone and heart health—K1, and two forms of K2, known as MK-4 and MK-7.

This complete vitamin K complex is vegan and non-GMO.

Additional Information

For bone and heart health

Non GMO validated

A potent form of K2, MK-7 works in two ways—it supports bone density and maintenance of normal vascular elasticity by helping direct proper amounts of calcium to the appropriate tissues. K2 MK-7 is highly bioavailable, lasts up to 12X longer than other forms of vitamin K, and is provided in this formula in a clinically backed dose.

Store in a cool, dry place.

SN2711 REV G167

Product Details

UPC / SKU 0 21078 02711 9
DSLD Entry Date 2017-11-20
Product Type Other Combinations
Form Tablet or Pill
DSLD ID 80669
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →